^
    Back
    Association details:
    Biomarker:AR overexpression
    Cancer:HER2 Positive Breast Cancer
    Regimen: (carboplatin + docetaxel + Herceptin (trastuzumab) + Perjeta (pertuzumab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Pers Med
    Title:

    Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

    Published date:
    02/11/2022
    Excerpt:
    A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was...positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], p = 0.005)....AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.
    DOI:
    https://doi.org/10.3390/jpm12020261